Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis

被引:31
作者
Paulke-Korinek, Maria [1 ,2 ]
Kollaritsch, Herwig [1 ]
Kundi, Michael [3 ]
Zwazl, Ines [1 ]
Seidl-Friedrich, Claudia [1 ]
Jelinek, Tomas [4 ]
机构
[1] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, A-1090 Vienna, Austria
[2] Fed Minist Hlth, Vienna, Austria
[3] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, A-1090 Vienna, Austria
[4] Berlin Ctr Travel & Trop Med, Berlin, Germany
关键词
Japanese encephalitis vaccine; Long-term protection; Low responder; IMMUNITY; CELLS; TBE;
D O I
10.1016/j.vaccine.2015.05.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Japanese Encephalitis (JE) virus occurs in wide regions of Asia with over 3 billion people living in areas at risk for JE. An estimated 68,000 clinical cases of JE occur every year, and vaccination is the most effective prophylactic measure. One internationally licensed vaccine containing the inactivated JE virus strain SA(14)-14-2 is lxiaro (R) (Valneva, Austria). According to recommendations, basic immunization consists of vaccinations on day 0, day 28, and a booster dose 12-24 months later. Protection in terms of neutralizing antibody titers has been assessed up to 12 months after the third dose of the vaccine. The current investigation was designed to evaluate antibody decline over time and to predict long-term duration of seroprotection after a booster dose. Method: In a preceding trial, volunteers received basic immunization (day 0, day 28) and one booster dose against JE 15 months later. A follow up blood draw 6 years following their booster dose was carried out in 67 subjects. For antibody testing, a 50% plaque reduction neutralization test (PRNT50-test) was used. PRNT50 values of 10 and above are surrogate levels of protection according to WHO standards. Result: Seventy-six months following the booster dose, 96% of the tested subjects had PRNT50 titers of 10 or higher. Geometric mean titer (GMT) was 148 (95% CI confidence interval: 107-207). Antibody titers were lower in volunteers 50 years of age and older. Vaccination history against other flaviviruses (yellow fever or tick borne encephalitis) did not significantly influence PRNT50 titers. A two-step log-linear decline model predicted protection against JE of approximately 14 years after the booster dose. Conclusion: Six years after a booster dose against JE, long-term protection could be demonstrated. According to our results, further booster doses should be scheduled 10 years following the first booster dose. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3600 / 3604
页数:5
相关论文
共 50 条
  • [31] Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine
    de Brito, Wagner Izidoro
    de Oliveira, Rode Martinho
    Silva, Jane
    Tubarao, Luciana Neves
    Dinis Ano Bom, Ana Paula
    Melgaco, Juliana Gil
    Pinto, Marcelo Alves
    Dutra Souto, Francisco Jose
    JOURNAL OF VIRAL HEPATITIS, 2023, 30 (07) : 615 - 620
  • [32] Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine
    Gilca, Vladimir
    De Serres, Gaston
    Boulianne, Nicole
    Murphy, Donald
    De Wals, Philippe
    Ouakki, Manale
    Trudeau, Gisele
    Masse, Richard
    Dionne, Marc
    VACCINE, 2013, 31 (03) : 448 - 451
  • [33] Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: Using PRNT50 as an endpoint for immunogenicity
    Reisler, Ronald B.
    Danner, Denise K.
    Gibbs, Paul H.
    VACCINE, 2010, 28 (12) : 2436 - 2441
  • [34] Field trial of primary and booster dose of inactivated vaccine against bovine respiratory bacteria in young Holstein calves
    Mori, Kazusa
    Kato, Toshihide
    Yokota, Osamu
    Ohtsuka, Hiromichi
    JOURNAL OF VETERINARY RESEARCH, 2020, 64 (02) : 223 - 230
  • [35] Vaccination against Borna Disease: Overview, Vaccine Virus Characterization and Investigation of Live and Inactivated Vaccines
    Duerrwald, Ralf
    Kolodziejek, Jolanta
    Oh, Djin-Ye
    Herzog, Sibylle
    Liebermann, Heinrich
    Osterrieder, Nikolaus
    Nowotny, Norbert
    VIRUSES-BASEL, 2022, 14 (12):
  • [36] Systemic and local antibodies induced by an experimental inactivated vaccine against bovine herpesvirus type 1
    Cilento, Maria do Carmo
    Pituco, Edviges Maristela
    Jordao, Ricardo Spacagna
    Ribeiro, Claudia Pestana
    Marchiori Filho, Moacir
    Montassier, Helio Jose
    CIENCIA RURAL, 2011, 41 (02): : 307 - 313
  • [37] Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination
    van Ravenhorst, Mariette B.
    Marinovic, Axel Bonacic
    van der Klis, Fiona R. M.
    van Rooijen, Debbie M.
    van Maurik, Marjan
    Stoof, Susanne P.
    Sanders, Elisabeth A. M.
    Berbers, Guy A. M.
    VACCINE, 2016, 34 (50) : 6309 - 6315
  • [38] Modeling long-term persistence after 8 years of hepatitis B booster vaccination in 5-to 15-year-old children
    Qiu, Yan
    Wu, Zi-Kang
    Wu, Jie
    Yao, Jun
    Liu, Ying
    Ren, Wen
    Sun, Yu-Jing
    Shen, Ling-Zhi
    Ren, Jing-Jing
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
  • [39] Antibody Persistence after 2-Dose Priming and Booster Response to a Third Dose of an Inactivated, Adjuvanted, Whole-Virion H5N1 Vaccine
    Lin, Jiang-Tao
    Li, Chang-Gui
    Wang, Xu
    Su, Nan
    Liu, Yan
    Qiu, Yuan-Zheng
    Yang, Meng
    Chen, Jiang-Ting
    Fang, Han-Hua
    Dong, Xiao-Ping
    Yin, Wei-Dong
    Feng, Zi-Jian
    JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (02) : 184 - 187
  • [40] Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents
    Saez-Llorens, Xavier
    Vaca, Diana Catalina Aguilera
    Abarca, Katia
    Maho, Emmanuelle
    Han, Linda
    Smolenov, Igor
    Dull, Peter
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (10) : E264 - E278